AVERITAS is a pharmaceutical company focused on Oncology, Neurology. Key products include MOVANTIK.
AVERITAS's Key Drugs
AVERITAS's core commercial portfolio centers on MOVANTIK, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.
AVERITAS's Recent FDA Approvals
New NDA/BLA approvals for AVERITAS over the last two years — novel drugs only, excluding generics and label supplements.
AVERITAS's Therapeutic Areas
AVERITAS's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AVERITAS's Top Competitors
AVERITAS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AVERITAS Pipeline Snapshot
Active clinical trials for AVERITAS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MOVANTIK leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2009-11-16
- Latest
- 2024-07-31
- Applications
- 2